Mylan: Roche's Herceptin biosimilar injunction will not stop production
Mylan says it will continue to manufacture and sell its Indian version of trastuzumab despite an injunction by Roche restricting reference to it as a biosimilar of Herceptin.
Archives for February 11, 2014
BIO weighs in with comments to US FDA on GPhA's biosimilar INN petition
Industry group BIO has responded to a petition by the Generic Pharmaceutical Association (GPhA) in the latest bout of the debate over the international non-proprietary name (INN) for biosimilars.
Barriers to entry in biosimilar market no problem, says Merck Serono
Merck Serono says it has the capabilities to compete in the biosimilar market but it is still a number of years away from a product launch.